Volume 31, Number 1—January 2025
Dispatch
Fatal Case of Crimean-Congo Hemorrhagic Fever, Portugal, 2024
Table 1
Category |
Description |
Patient information and event timeline |
|
Risk factors |
Subsistence farmer; animal contact (chicken and donkey); living in a rural area |
Comorbidity |
Hypertension, hypercholesterolemia, and prostate hypertrophy |
Event |
|
Epidemiologic exposure |
Patient reports tick removal on Jul 10 |
Symptoms onset |
Fever and myalgia, Jul 11 |
Presumptive diagnosis |
Mediterranean spotted fever, Jul 12 |
Signs and symptoms |
Fever, myalgia, nausea, vomit, and diarrhea, Jul 16 |
Petechiae, mild epistaxis, and gingival bleeding, Jul 18 |
|
Test results |
|
Imaging, Jul 18 |
Pleural effusion, lung widespread infiltrates, ascites, no hepatomegaly, or splenomegaly |
Serum sample data, Jul 19 |
|
Real-time PCR |
|
CCHFV commercial |
Ct 21.2 |
CCHFV in-house |
Ct 28.7 |
Rickettsia spp. |
Negative |
Serology† |
|
CCHFV-GPC IgM |
Negative (<16) |
CCHFV-N IgM |
Pos itive(128) |
CCHFV-GPC IgG |
Negative (<32) |
CCHFV-N IgG |
Negative (<32) |
SFGR IgM |
Negative (<32) |
SFGR Rickettsia IgG | Positive (128) |
*CCHFV, Crimean-Congo hemorrhagic fever virus; Ct, cycle threshold; GPC, glycoprotein; N, nucleoprotein; SFGR, spotted fever group Rickettsia. †Cutoff values: CCHFV IgM>16, CCHFV IgG>32, Rickettsia IgM>32, Rickettsia IgG>128.
1These first authors contributed equally to this article.
Page created: November 15, 2024
Page updated: December 22, 2024
Page reviewed: December 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.